Existing drugs studied in patients with rare immune diseases
This month the first study within the DRIMID consortium (DRIMID stands for Drug Rediscovery for Rare Immune Mediated Inflammatory Diseases) has started. This study will investigate the efficacy and safety of the drug filgotinib (approved for treatment of rheumatoid arthritis and ulcerative colitis) in three rare immune diseases (Behçet’s disease, idiopathic inflammatory myositis, IgG4-related disease). DRIMID aims to investigate whether this drug – despite the absence of formal drug approval – can also be used to treat these rare immune diseases.